Image
BIMZELX® (bimekizumab)▼: Moderate to severe plaque psoriasis
BIMZELX® is indicated for: moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Bimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).1
BIMZELX: The opportunity for complete, fast and lasting skin clearance1,2
- 68.2% achieved PASI 100 at Week 16*1
- 75.9% of patients achieved PASI 75 at Week 4*1
- 82% of week 16 PASI 100 responders maintained this response up to 3 years2
BIMZELX® (bimekizumab) was well tolerated, the most frequently reported adverse reactions were: upper respiratory tract infections (14.5%, 14.6%, in plaque psoriasis (PSO), and psoriatic arthritis (PsA) respecively) and oral candidiasis (7.3%, 2.3% in PSO and PsA respectively).1 Refer to the SmPC for the full list of adverse events.
* co-primary endpoints PASI 90 and IGA 0/1 at week 16.
Image
Consider BIMZELX for your eligible patients with moderate to severe plaque psoriasis who want the opportunity for complete, fast and lasting skin clearance‡4
‡ Complete skin clearance defined as PASI 100. Response at Week 16 in patients randomised to BIMZELX 320 mg Q4W at baseline (NRI).4
NOW ALSO LICENSED FOR USE IN PsA
Find out more about BIMZELX in psoriatic arthritis
BIMZELX is the first biologic designed to selectively and directly inhibit both IL-17A and IL-17F1,3
MECHANISM OF ACTION
Date of preparation: October 2023
References
1. BIMZELX (bimekizumab) Summary of Product Characteristics.
2. Strober, B., et al. [BE BRIGHT open label extension] Br J Dermatol. 2023. 188(6): 749-759.
3. National Institute for Clinical Excellence. NICE TA723; Available online from: https://www.nice.org.uk/guidance/ta723/. Accessed November 2023.
4. Strober, B., et al. AAD 2022. Presentation 34321.
5. Gordon, K.B., et al. EADV 2022. Poster 1569.